- <u>-</u>		<u> </u>		JC04 Rec'd PCT/PTO 3 0 May 200						
	ORM PTO	2000)								
*	U	TRANSMITTAL LETTE	ER TO THE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)						
7	DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 10/069,598									
IN	TERNA	ATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
		PCT/JP00/06172	08/09/2000	08/09/1999						
TI	TITLE OF INVENTION									
	MATERIAL FOR USE IN EXTRACORPOREAL CIRCULATION, ADSORBENT, REMOVAL UNIT AND REMOVING METHOD FOR									
AF	APPLICANT(S) FOR DO/EO/US									
Ţ.			SHIMIZU et al							
Ap	plican	it herewith submits to the Unite	ed States Designated/Elected Office (DO/EC	O/US) the following items and other information:						
1.	_		of items concerning a filing under 35 U.S.C.							
2.	. 🛛		SEQUENT submission of items concerning a							
3.	. 🗆	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.								
4.	. 🗆		by the expiration of 19 months from the priori	rity data (Article 21)						
5.	_		ration as filed (35 U.S.C. 371(c)(2)).	ity date (Article 31).						
	a.			national Rureau)						
	b.	The international bureau).								
	c.	is not required, as the application was filed in the United States Receiving Office (RO/US).								
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).								
	a.	is attached hereto.		00 0.0.0. 01 1(0)(2)).						
	b.	has been previously sul	ubmitted under 35 U.S.C. 154(d)(4).							
7.			of the International Application under PCT Art	rticle 19 (35 U.S.C. 371(c)(3))						
	a.		equired only if not communicated by the Intern							
	b.		ted by the International Bureau.	, , , , , , , , , , , , , , , , , , ,						
	C.		nowever, the time limit for making such amen	ndments has NOT expired.						
	d.	have not been made an		, and 112 / 3.p.132.						
8.			tion of the amendments to the claims under F	PCT Article 19 (35 U.S.C. 371(c)(3)).						
9.			inventor(s) (35 U.S.C. 371(c)(4)).	( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )						
10.		A English language translatio	on of the annexes of the International Prelimi	ninary Examination Report under PCT						
	Article 36 (35 U.S.C. 371(c)(5)).									
	Item	ns 11 To 20 below concern d	document(s) or information included:							
11.	_		atement under 37 C.F.R. 1.97 and 1.98.							
12.				oliance with 37 C.F.R. 3.28 and 3.31 is included.						
13.		A FIRST preliminary amendment.								
14.	$\boxtimes$	A SECOND or SUBSEQUEN	IT preliminary amendment.							
15.	_	A substitute specification.								
16.		A change of power of attorney	y and/or address letter.							
17.		A computer-readable form of	the sequence listing in accordance with PCT	T Rule 13ter.2 and 35 U.S.C. 1.821-1.825.						
18.			ished international application under 35							
19.			language translation of the international app							
20.	$\boxtimes$	Other items or information. St	Statement w/paper and computer readable co	ODV of Sequence Listing: Copy of Notification of						
Miss	sing Pa	arts; Statement to Support Filir	ng and Submission in Accordance with 37 Cl	FR §§1.821-1.825						

U.S. APPLICATION NO. (If kno		ران.	INTERNATIONAL APPLICAT			ATT	ORNEY'S DOCKET 2109-24	NUN	BER
	10/069,598 PCT/JP00/06172  1.			7	ALCULATIONS	PTC	USE ONLY		
			1-(5):			۲	ALCOLATIONS		- COE CITE!
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):  Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1040.00									
			7 C.F.R. 1.482) not paid to 5(a)(2)) paid to USPTO		. \$740.00				
but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO\$740.00  International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$710.00									
International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)									
ENTER APPROPRIATE BASIC FEE AMOUNT =						\$	0.00		
months from the earliest	claimed priority	date (37 (				\$	0.00		
CLAIMS	NUMBER F		NUMBER EXTRA		ATE			· —	
Total Claims	20	-20 =	0	X	\$18.00	<u>  \$</u> _	0.00		
Independent Claims MULTIPLE DEPENDEN	3   T CL AIMS(S) (if	-3 = ]	0	X	<u>  \$84.00</u> 30.00	6	0.00	├—	
WOLTIPLE DEPENDEN	I CLAINS(S) (II	аррисавіє	TOTAL OF AB			\$	0.00 <b>0.00</b>	<del> </del>	<del></del>
Applicant claims sn are reduced by 1/2.		. See 37 (	CFR 1.27. The fees indica		<u>DEATIONS</u>	Ψ	0.00		
are reduced by 1/2.				S	UBTOTAL =	\$	0.00	$\vdash$	
Processing fee of \$130.0 months from the earliest			sh Translation later than			Ť	0.00		-
111011110111111111111111111111111111111	ciamica priority	44.0 (0.		OTAL NATIO	ONAL FEE =	\$	0.00		
			R. 1.21(h)). The assignr F.R. 3.28, 3.31). <b>\$40.0</b> 0		+	\$	0.00		
			ed Application (\$1280.00	- Small Entit		\$	0.00		
			T01	AL FEES E	NCLOSED =	\$	0.00		
						Α	mount to be: refunded	\$	/ 
<del> </del>						┢		\$	
a.   A check in the amount of \$0.00 to cover the above fees is enclosed.									
b.   Please charge	my Deposit Acc	ount No.	14-1140 in the amount of	\$ to co	over the above	fee	S.		
			to charge any additional for			l, or	credit any		İ
			1140. A <u>duplicate</u> copy of			·orn	orated by refe	once	in this
d.   The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.									
			7 C.F.R. 1.494 or 1.495 h		met petition	on 1	to revive (37 C	.F.R	. 1.137(a)
or (b)) must be filed and granted to restore the application to pending status.									
SEND ALL CORRESPONDENCE TO:  SIGNATURE									
NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 <sup>th</sup> Floor									
Arlington, Virginia 22201-4714							1		
Telephone: (703) 816-4000 Arthur R. Crawford									
ARC:eaw NAME									l
25,327						May 30, 20	02		
					RATION NUMBE	R	Date		

09/08/1999





### UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patiens, Box PCT United States Patient and Trademark Office Washington, D.C. 20233

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY.	DOCKET NO.
10/069,598	S. Shimizu	2	109-24
		INTERNATIONAL APPI	LICATION NO.
		PCT/JP00/0	6172
Arthur R Crawford	<u></u>	LA EULING DATE	DRIGHTY DATE

Arthur R Crawford Nixon & Vanderhye 1100 North Glebe Road 8th Floor Arlington, VA 22201-4714

CONFIRMATION NO. 3579 371 FORMALITIES LETTER

08/09/2000

\*OC000000007973332\*

Date Mailed: 04/29/2002

# NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- . U.S. Basic National Fees
- Priority Document
- Assignee Statement
- Biochemical Sequence Listing
- · Copy of IPE Report
- · Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- · Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

## DOCKETED

CLT/MATTER#_	2109-24
MAIL DATE 4/2	9/2
DUE DATE JUANE	29,2002
FINAL DEADLINE	Nov. 29, 2007
DOCKETED BY_	MESOR
	TO TO THE PERSON OF THE PERSON

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

• The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the

requirements for such a discussure as set forth in 37 CFR 1.821-1.825 for the following reason(s):



- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
  - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase Patentin Software, call (703) 306-2600
  - For Patentln Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

#### PATRICIA A BOOKER

Telephone: (703) 305-3738

# PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/069,598	PCT/JP00/06172	2109-24

FORM PCT/DO/EO/905 (371 Formalities Notice)